AstraZeneca Pharma to launch COPD drug in January 2025; stock up 3%

Shares of AstraZeneca Pharma India rose 2.98 per cent at Rs 6,588.35 per share on the BSE in Tuesday's intraday deals

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
SI Reporter New Delhi
2 min read Last Updated : Nov 19 2024 | 10:49 AM IST
Shares of AstraZeneca Pharma India rose 2.98 per cent at Rs 6,588.35 per share on the BSE in Tuesday’s intraday deals. This came after the company announced that it will launch Breztri Aerosphere in January 2025 in India. 
 
The pharmaceutical company had received the import and market permission from the Drugs Controller General of India for Breztri Aerosphere on December 2, 2023.
 
“We wish to further update that AstraZeneca Pharma India Limited will launch Breztri Aerosphere in January 2025 in India. Breztri Aerosphere is indicated for the maintenance treatment to relieve symptoms and prevent exacerbations in adult patients with chronic obstructive pulmonary disease (COPD),” the company said in an exchange filing on Monday.
 
Q2 results
AstraZeneca Pharma India recorded a jump in its revenues in the second quarter of financial year 2024-25 (Q2FY25). Revenue from operations grew by 31 per cent year-on-year to Rs 408 crore in the second quarter of FY25, with first-half revenue reaching Rs 795.5 crore, driven by strong performance across the oncology, biopharmaceuticals, and rare disease segments.
 
Profit before exceptional items and tax stood at Rs 51 crore for Q2FY25, while profit after tax (PAT) recovered to Rs 38.4 crore from a net loss of Rs 11.8 crore in Q1. However, PAT declined 27 per cent year-on-year compared to Rs 52 crore in the same quarter last year.

AstraZeneca Pharma share price history

The company’s stock has outperformed the market year to date as it has risen 16 per cent, while gaining 40 per cent in the last one year. In comparison BSE Sensex has risen 8.2 per cent year to date and 18.8 per cent in a year. 
 
The company has a total market capitalisation of Rs 16,345 crore. AstraZeneca Pharma shares are trading at a price to earnings multiple of 195.24 times and at an earning per share of Rs 32.77. 
 
At 10:43 AM; the shares of the company pared all their gains and slipped in red, trading 2.50 per cent higher at Rs 6,557.75 a piece. By comparison, the BSE Sensex was down 1.13 per cent at 78,216.20 level. 
   
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Buzzing stocksAstraZenecaMarkets Sensex NiftyBSE NSE

First Published: Nov 19 2024 | 10:48 AM IST

Next Story